Karen E. Elkind-Hirsch

Karen E. Elkind-Hirsch

Auto-generated profile, based on publicly available information

Karen E. Elkind-Hirsch

DexCom Inc

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2008 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
KEKaren Elkind-Hirsch
Karen Elkind-Hirsch
OMOry Marrioneaux
Ory Marrioneaux
MBMadhu Bhushan
Madhu Bhushan
DVDenise Vernor
Denise Vernor
RBRajat Bhushan
Rajat Bhushan
Context: Insulin resistance and obesity are common features of the polycystic ovary syndrome (PCOS). Weight loss and use of insulin-lowering drugs have been shown to improve both reproductive and metabolic aspects of PCOS. Objective: We evaluated exenatide (EX) and metformin (MET), alone and in combination (COM), on menstrual cyclicity, hormonal parameters, metabolic profiles, and inflammatory markers in overweight, insulin-resistant women with PCOS. Design, Setting, and Participants: Sixty overweight oligoovulatory women with PCOS (body mass index > 27; 18–40 yr) were randomized to one of three treatment groups: MET [1000 mg twice daily (BID)], EX (10 μg BID), or COM (MET 1000 mg BID, EX 10 μg BID) for 24 wk. The primary outcome was menstrual frequency; secondary outcome measures included changes in ovulation rate, insulin action, anthropometric measures, androgen levels, and inflammatory markers. Results: Forty-two (70%) patients completed the study. COM therapy was superior to EX or MET monotherapy in improving menstrual cyclicity, ovulation rate, free androgen index, and insulin sensitivity measures and reducing weight and abdominal fat. Both EX arms were more effective in promoting weight loss than MET (P = 0.003). Conclusions: COM appears better than either EX or MET alone on menstrual cycle frequency and hormonal and metabolic derangements. A marked decrease in central adiposity could partly explain the improvements in reproductive function, insulin-glucose parameters, and adiponectin observed in these overweight women with PCOS treated with COM therapy. Larger trials of longer duration are warranted to assess the long-term efficacy and safety of combined EX-MET therapy in overweight women with PCOS.

13 June 2022 in Fertility and Sterility
Verified
Journal Article
Open access
KEKaren E. Elkind-Hirsch
Karen E. Elkind-Hirsch
NCNeil Chappell
Neil Chappell
DSDonna Shaler
Donna Shaler
JSJohn Storment
John Storment
DBDrake Bellanger
Drake Bellanger
To study the efficacy and safety of the GLP-1 analog liraglutide 3 mg (LIRA 3 mg) vs. placebo (PL) for reduction of body weight (BW) and hyperandrogenism in women with obesity and polycystic ovary syndrome (PCOS). Randomized, double-blind, placebo-controlled trial. Hospital-based outpatient endocrine and metabolic center. Women diagnosed with PCOS (NIH criteria) were randomly assigned to LIRA 3 mg (n = 55) or PL (n = 27) once daily for 32 weeks with lifestyle intervention. Study visits at baseline and 32 weeks included BW and body composition by dual-energy x-ray absorptiometry. Oral glucose tolerance tests were done with sex steroids, free androgen index (FAI), and lipids measured in the fasting sample. The primary end points were changes in BW and FAI. Safety was assessed in all patients who received at least one dose of the study drug. Change in BW from baseline to week 32 was -5.7% (±0.75) with LIRA 3 mg vs. -1.4% (±1.09) with PL. At week 32, more participants on LIRA 3 mg than on PL achieved at least 5% weight reductions (25 of 44 vs. 5 of 23). Free androgen index significantly reduced with LIRA 3 mg compared with the PL where the mean FAI slightly increased. Gastrointestinal events, which were mostly mild to moderate, were reported in 58.2% of the LIRA 3 mg-subjects and 18.5% of PL subjects. LIRA 3 mg once daily appears superior to PL in reducing BW and androgenicity and improving cardiometabolic parameters in women with PCOS and obesity. NCT03480022.

13 September 2017 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
Leanne M. RedmanLeanne M. Redman
Leanne M. Redman
AGAnne Gilmore
Anne Gilmore
JBJeffrey Breaux
Jeffrey Breaux
DTDiana M Thomas
Diana M Thomas
KEKaren Elkind-Hirsch
Karen Elkind-Hirsch
CMCorby K. Martin
Corby K. Martin
Mobile and tablet apps, ubiquitous and pervasive computing, wearable computing and domotics for health.

7 June 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
KEKaren E Elkind-Hirsch
Karen E Elkind-Hirsch
NCN Chappell
N Chappell
ESEricka Seidemann
Ericka Seidemann
JSJohn Storment
John Storment
DBDrake Bellanger
Drake Bellanger
Context: Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors reduce weight and improve insulin sensitivity via different mechanisms. Objective: The efficacy of once-weekly exenatide (EQW) and dapagliflozin (DAPA) alone and coadministered (EQW/DAPA), DAPA/extended-release (ER) metformin (DAPA/MET), and phentermine topiramate extended release (PHEN/TPM) on metabolic parameters, body composition, and sex hormones were examined in obese women with PCOS. Methods: Nondiabetic women (n = 119; aged 18-45 years) with a body mass index (BMI) greater than 30 and less than 45 and polycystic ovary syndrome (National Institutes of Health criteria) were randomly assigned in a single-blinded fashion to EQW (2 mg weekly); DAPA (10 mg daily), EQW/DAPA (2 mg weekly/10 mg daily), DAPA (10 mg)/MET (2000 mg XR daily), or PHEN (7.5 mg)/TPM (46 mg ER daily) treatment for 24 weeks. Study visits at baseline and 24 weeks included weight, blood pressure (BP), waist (WC) measures, and body composition evaluated by dual-energy x-ray absorptiometry (DXA). Oral glucose tolerance tests were conducted to assess glycemia and mean blood glucose (MBG), and compute insulin sensitivity (SI) and secretion (IS) measures. Sex steroids, free androgen index (FAI), and lipid profiles were measured in the fasting sample. Results: EQW/DAPA and PHEN/TPM resulted in the most loss of weight and total body fat by DXA, and WC. Despite equivalent reductions in BMI and WC with PHEN/TPM, only EQW/DAPA and EQW resulted in significant improvements in MBG, SI, and IS. Reductions in fasting glucose, testosterone, FAI, and BP were seen with all drugs. Conclusion: Dual therapy with EQW/DAPA was superior to either alone, DAPA/MET and PHEN/TPM in terms of clinical and metabolic benefits in this patient population.

8 June 2009 in BMC Pregnancy and Childbirth
Verified
Journal Article
Open access
PDF file
EHEmily Harville
Emily Harville
XXXu Xiong
Xu Xiong
GPGabriella Pridjian
Gabriella Pridjian
KEKaren Elkind-Hirsch
Karen Elkind-Hirsch
PBPierre Buekens
Pierre Buekens
Natural disaster is often a cause of psychopathology, and women are vulnerable to post-traumatic stress disorder (PTSD) and depression. Depression is also common after a woman gives birth. However, no research has addressed postpartum women's mental health after natural disaster.

25 June 2009 in Maternal and Child Health Journal
Verified
Journal Article
Closed access
PDF file
MTMichael T. Tees
Michael T. Tees
EHEmily Harville
Emily Harville
XXXu Xiong
Xu Xiong
PBPierre Buekens
Pierre Buekens
GPGabriella Pridjian
Gabriella Pridjian
KEKaren Elkind-Hirsch
Karen Elkind-Hirsch